A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Nucleotide excision repair (NER) is crucial for DNA damage repair, preventing mutations linked to cancer and aging.
• Deficient NER (dNER) can arise without detectable gene mutations, potentially being more common than previously thought.

Purpose of the Study:

• To develop a gene expression signature for predicting functional NER capacity.
• To identify novel therapeutic strategies and drugs targeting dNER.
• To explore the impact of GSK3 inhibition on NER function.

Main Methods:

• Utilized isogenic dNER model cell lines to establish a predictive gene expression signature.
• Screened compounds to identify those inducing the dNER signature.
• Investigated the effect of GSK3 inhibition on NER function and its synergy with cisplatin.
• Employed the dNER signature as a platform for discovering drugs synthetically lethal with dNER.

Main Results:

• Successfully established a gene expression signature that accurately predicts NER capacity in cell lines and patient samples.
• Discovered that GSK3 inhibition impairs NER function, showing synergistic effects with cisplatin.
• Identified and validated novel drugs that are synthetically lethal with dNER defects.

Conclusions:

• The developed gene signature serves as a dynamic predictor of NER function.
• This approach facilitates therapeutic stratification for cancer treatment.
• The study opens avenues for novel biological insights and drug development in human tumors with NER deficiencies.